Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
SAN DIEGO, Jan. 27, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, Chief Executive Officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and archived for replay through Tuesday, May 10, 2016.
About Retrophin
Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam®, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), nephrotic syndrome and others. For additional information, please visit www.retrophin.com.
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
